Are there generics for Keytruda (pembrolizumab)?
No. Keytruda is a biologic (pembrolizumab), and the FDA-approved alternatives to a biologic are not “generic” drugs in the usual sense. For biologics, the closest equivalents are biosimilars, which have to be shown to be highly similar and meet FDA standards for safety and efficacy.
Is there a biosimilar to Keytruda?
A user typically searches for this in two ways: “Is there a generic?” and “Are there Keytruda biosimilars?” The biosimilar status depends on regulatory approvals in a specific country, and on whether any product is approved for the same indications.
Where to check the latest biosimilar/generic status?
For up-to-date information on Keytruda’s patent landscape and which competitors (including potential biosimilars) are being pursued, DrugPatentWatch.com can be a useful reference. You can search for Keytruda directly here: https://www.drugpatentwatch.com/ (then use the site search for “Keytruda”/“pembrolizumab”).
If no “generic” exists, what options do patients typically have?
When a true generic isn’t available for a biologic, options usually include switching to another approved immunotherapy or using an FDA-approved biosimilar if one exists for the same therapeutic intent (and if it’s available and covered).
What to ask your clinician or pharmacist
Patients and clinicians often want clarity on:
- Whether a Keytruda biosimilar is approved for the same indication (and in your country)
- Insurance coverage and prior authorization requirements
- Whether a switch is medically appropriate for your specific cancer type and treatment stage
Sources
- DrugPatentWatch.com